SELL-SIDE CONSENSUS - OCT 2025											
	2024 ac	tuals		H2 2025			2025.			2027	2028
			3 contributors			3 contributors			2026 3 contributors	3 contributors	2 contributors
	H1	FY	Average	Highest	Lowest	Average	Highest	Lowest	Average	Average	Average
Not Salas	440.7	011.0	410.1	410.1	410.1	970 5	904.4	950.6	010 4	942.6	992.1
Net Sales	448.7 -9.6%	911.9 -10.0%	412.1 -8.2%	412.1 -8.2%	412.1 -8.2%	870.5 -4.5%	894.4 -1.9%	850.6 -6.7%	818.4 -6.0%	843.6 3.1%	882.1 3.3%
Year on Year change	0.0%	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Of which API Solutions	332.4	663.6	299.7	299.7	299.7	619.0	651.5	598.4	543.1	551.8	572.5
	-8.3%	-8.8%	-9.8%	-9.8%	-9.8%	-6.7%	-1.8%	-9.8%	-12.2%	1.6%	3.0%
- API Solutions - Other Clients	168.6	354.1	175.9	<i>17</i> 5.9	<i>17</i> 5.9	382.0	395.9	363.4	377.0	401.2	427.3
	-0.7%	-1.7%	4.3%	4.3%	4.3%	7.9%	11.8%	2.6%	-1.2%	6.5%	6.1%
- API Solutions - Sanofi	163.7	309.5	123.8	123.8	123.8	237.0	255.6	220.4	166.2	150.6	145.2
	-15.0%	-15.7%	-24.3%	-24.3%	-24.3%	-23.4%	-17.4%	-28.8%	-30.7%	-9.0%	-4.9%
Of which CDMO	116.4	248.3	112.4	112.4	112.4	251.5	259.4	243.0	275.2	299.5	336.8
	-13.3%	-13.1%	-3.4%	-3.4%	-3.4%	1.3%	4.5%	-2.1%	9.5%	8.8%	8.7%
- CDMO - Other Clients	72.3	135.6	60.2	60.2	60.2	126.7	130.0	125.0	141.2	155.0	179.1
	-12.7%	-24.9%	-16.8%	-16.8%	-16.8%	-6.6%	-4.2%	-7.8%	11.6%	9.7%	11.3%
- CDMO - Sanofi	44.1	112.7	52.2	52.2	52.2	124.8	134.3	118.0	134.0	144.5	157.7
	-14.2%	7.0%	18.5%	18.5%	18.5%	10.8%	19.2%	4.7%	7.4%	7.8%	6.0%
Of which other clients	240.9	489.7	236.0	236.0	236.0	508.7	520.9	493.3	518.2	556.2	606.4
or which carer careries	-4.6%	-9.4%	-2.0%	-2.0%	-2.0%	3.9%	6.4%	0.7%	1.9%	7.4%	7.6%
Of which Sanofi	207.8	422.2	176.1	176.1	176.1	361.8	373.5	354.7	300.2	295.1	302.9
	-14.9%	-10.7%	-15.3%	-15.3%	-15.3%	-14.3%	-11.5%	-16.0%	-17.2%	-1.5%	0.7%
Other Revenues	2.2	7.3	2.4	2.4	2.4	2.4	4.9	0.0	1.7	1.7	0.0
GROSS PROFIT	98.0	142.4	76.6	76.6	76.6	147.6	161.4	140.5	149.3	170.0	179.2
GP Margin	21.8%	15.6%	18.6%	18.6%	18.6%	16.9%	18.0%	16.2%	18.3%	20.2%	20.4%
EBITDA	-1.4	-43.6	5.0	5.0	5.0	17.3	36.3	-0.2	23.4	69.5	130.6
Restructuring costs	49.0	-94.0	34.6	34.6	34.6	57.0	74.2	40.0	65.3	47.3	0.0
CORE EBITDA	47.6	50.4	39.5	39.5	39.5	74.3	76.3	72.6	88.7	116.8	130.6
CORE EBITDA Margin	10.6%	5.5%	9.6%	9.6%	9.6%	8.5%	8.5%	8.5%	10.8%	13.9%	14.9%
Operating Income	-33.4	-120.4	-27.8	-27.8	-27.8	-51.3	-29.0	-69.5	-8.5	-1.3	60.9
Finance revenues/costs	-8.1	-19.2	-2.3	-2.3	-2.3	-14.1	-7.2	-19.8	-13.2	-12.8	-17.6
Income before tax	-41.5	-139.6	-30.1	-30.1	-30.1	-65.4	-48.8	-84.7	-57.8	-14.1	43.3
Income tax Expense	6.7	9.0	1.5	1.5	1.5	4.5	5.9	3.1	7.7	2.2	-6.2
Net Income	-34.8	-130.6	-28.5	-28.5	-28.5	-60.9	-45.7	-78.8	-50.1	-11.8	37.1
Average number of shares(m)	94.3	0.0	94.6	94.6	94.6	94.9	95.5	94.5	94.9	94.9	95.0
EPS	-0.37	-1.38	-0.30	-0.30	-0.30	-0.64	-0.48	-0.82	-0.53	-0.12	0.39
CAPEX	61	108	38	38	38	95	100	91	80	81	81
Cash Flow before Financing	10	15				-14	31	-60	4	-3	38
5 man 1 man	10					2-7	31	30		3	

Forward-Looking Statements - The information above is a nonexhaustive summary of the estimates of the financial analysts covering Euroapi. These estimations have been compiled by Euroapi and are provided for information purposes only. The presence of this consensus on Euroapi website does not constitute validation or approval of the forecast presented, or of any element thereof, by Euroapi. This information is not and cannot be construed as an invitation or a recommendation to buy or sell securities or to conclude any transaction of any kind.